Optimization of concomitant medication in Fabry cardiomyopathy.
We describe a male patient with Fabry disease and use this case study to illustrate the importance of a detailed cardiovascular evaluation and the role of supportive therapy in routine management of the disease. The major areas of discussion include the management of exertional chest pain, progressive heart failure and the diagnosis and treatment of atrial and ventricular arrhythmia.


CONCLUSIONS
In the era of enzyme replacement therapy, conventional pharmacological and device-based therapies remain central to the management of cardiovascular symptoms and the prevention of complications, such as arrhythmia and stroke.
Close
Lydia
L
The Heart Hospital, University College, London, UK.
Elliott
Perry
P
D002317:Cardiovascular Agents / Q000627:therapeutic use*; D000795:Fabry Disease / Q000150:complications*; D006331:Heart Diseases / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D008297:Male; D008875:Middle Aged
D002317:Cardiovascular Agents